Better Health for All

Revolution Medicines is a clinical-stage oncology company focused on developing targeted therapies for RAS mutant cancers.

Its entire business is devoted to health improvement, with all investigational products aimed at treating severe diseases like pancreatic, colorectal, and non-small cell lung cancer. Daraxonrasib, one of its investigational drugs, has shown promising clinical outcomes with a median Progression-Free Survival of 8.8 months and median Overall Survival of 14.5 months in pancreatic ductal adenocarcinoma. The company has no revenue from products with established negative health outcomes, as its products are investigational cancer treatments. However, the efficacy and safety of its investigational drugs have not yet been established, and clinical trials involve assessing safety and tolerability, with combination cohorts introducing additional safety monitoring complexity in a population predisposed to hepatic and GI toxicities. The company's Code of Business Conduct and Ethics emphasizes safeguarding confidential information, including electronic data files, but specific health data protection measures are not detailed. The company is investing significantly in health innovation, with 2024 full-year R&D expenses of $592.2 million and a $2 billion flexible funding agreement to support global development. Clinical trials target patients with advanced cancers who have exhausted or cannot tolerate standard options. The company provides a link to ClinicalTrials.gov, suggesting adherence to public disclosure standards, but specific ethical conduct details for trials are not provided.

Fair Money & Economic Opportunity

Revolution Medicines, Inc. is a clinical-stage oncology company focused on developing cancer therapies. Its core business does not involve providing financial services such as lending, deposits, or insurance to consumers. Therefore, all KPIs related to fair money and economic opportunity, which are designed for financial institutions, are not applicable to the company.

The company reported a net loss of $600.1 million in 2024 and $436.4 million in 2023, indicating no profits available for community finance reinvestment.

Fair Pay & Worker Respect

Revolution Medicines, Inc. reported a CEO to median employee pay ratio of 28:1 for the 2024 fiscal year.

Employee reviews on Glassdoor indicate an overall rating of 3.4 out of 5 stars, which translates to approximately 68% engagement. There are no mentions of regulatory actions, violations, or fines related to labor laws or human rights in the provided articles. No specific quantitative data was available for living wage coverage, collective bargaining share, safety incident rate, pay equity ratio, turnover rate, insecure contract share, or health insurance coverage.

Kind to Animals

The company engages in animal testing.

However, no specific quantitative data on the volume of animals used, details of its animal testing policy, or information regarding the use of alternative testing methods is provided. There is also no evidence concerning cruelty-free certifications, humane certifications for operations, wildlife conservation impact, ethical input substitution, supplier audits, cage-free sourcing, R&D investment in animal-free technologies, animal agriculture ethics, or engagement in animal-free R&D collaborations or public policy.

Planet-Friendly Business

The provided articles do not contain specific, quantitative data points for any of the Planet-Friendly Business KPIs. explicitly states that no quantitative data relevant to the specified metrics is available.

mentions "GHG Emissions" as both a positive and negative impact category in a general sense, but provides no specific numerical data on emissions, reductions, or targets that could be used for scoring against any KPI.

Respect for Cultures & Communities

The provided articles consist solely of job postings for Revolution Medicines, Inc., detailing job descriptions, required skills, and salary ranges.

No information or specific data points related to the company's engagement with local or indigenous communities, cultural preservation efforts, community investments, grievance mechanisms, or any other metrics relevant to the 'Respect for Cultures & Communities' value were found.

Safe & Smart Tech

No specific, quantifiable evidence was found across the provided articles to assess Revolution Medicines, Inc. against the 'Safe & Smart Tech' ethical value. The articles primarily focus on financial performance and general corporate information, with limited details on cybersecurity, data privacy, or AI ethics. While one article mentions that cybersecurity awareness training is provided to employees and contractors, and that the company performs periodic vulnerability scans and penetration tests, these statements lack the quantitative data (e.g., percentage of employees trained, effectiveness metrics, patching timeframes, scope of testing) required by the rubric's scoring thresholds.

Similarly, claims of aligning with industry standards or not identifying material risks from known cybersecurity threats are not specific enough to score against KPIs that require concrete data on breaches, incidents, or defined periods of no issues.

Zero Waste & Sustainable Products

The provided articles contain information about a company named 'Revolution Sustainable Solutions' or 'Revolution Company' which is involved in plastic recycling and sustainable products (Articles , , , , ). However, the company being assessed is Revolution Medicines, Inc. (RVMD.US), a clinical-stage oncology company.

explicitly states that its investor relations page (ir.revmed.com) contains no information relevant to 'Zero Waste & Sustainable Products' for Revolution Medicines, Inc. Therefore, no specific, concrete data points for RVMD.US were found in any of the provided articles for any of the KPIs under this value.